Be Familiar With Adakveo and Oxbryta for Sickle Cell Disease

New sickle cell meds Adakveo (ah-DAK-vee-oh, crizanlizumab) and Oxbryta (oks-BRYE-tuh, voxelotor) may pop up on home med lists.

They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.

And they'll compete with oral Endari (L-glutamine)...which seems to reduce pain crises and possibly hospitalizations.

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals